Mark Robinson <[email address]>
FW: SleepDrops International Callaghan Funding Grant follow up
7 messages
Tony Vujnovich <[email address]>
19 February 2021 at 17:58
ReTo: "[email address]" <[email address]>
Hi Mark,
ased
Are you dealing with this company, I understood you were dealing with Mark Olley, the previous manager.
Regards
under the Official Information Act 1982
Tony Vujnovich
From: Kirsten Taylor <
[email address]>
Sent: Thursday, 18 February 2021 6:21 PM
To: Tony Vujnovich <
[email address]>
Subject: FW: SleepDrops International Callaghan Funding Grant follow up
Importance: High
HI Tony, I hope you are doing great.
I am once again following up.
SleepDrops has heard back from AUT in respect of them doing some trials for us to develop products and open up
new market opportunities.
Can you please get back to me about how to progress this?
I understand you may be busy and may not be the best person.
Could you please advise who we should get hold of or how we can apply for this support?
Thank you
Kind regards
Kirsten
From: Kirsten Taylor
Sent: Wednesday, 9 December 2020 4:45 PM
To: [email address]
Subject: SleepDrops International Callaghan Funding Grant follow up
HI Tony, I trust you are doing well.
9(2)(a) - Privacy
I am very keen to progress
opportunities with research and grants and or match funding. We are working with the AUT research team
and have 3 clinical trials proposed for the 2021 year.
Logically this is expensive from both a cash and an in house resource perspective.
We would gratefully accept any and all support that we can get.
How can we apply for and get funding support from Callaghan?
Re
During our face to face meeting you suggested you were going to get someone who knew more about the
natural health space to get in touch with us.
I am unsure how things have progressed between yourself and Mark, so I apologise if I am out of the loop but
ased
the last communication Mark and I had about this was that he had not heard anything as yet.
Is there something more you are awaiting from us?
Would you like to meet in person?
under the Official Information Act 1982
Thanks again Tony and I look forward to working out how we can research and bring new products to market
for the betterment of NZ health and also NZ inc.
Kind regards
Kirsten
Thanks and Best Regards,
Kirsten
Kirsten Taylor
CEO and Founder
SleepDrops International Limited
Board of Directors – Auckland Business Chamber
Trustee – Auckland Santa Parade Trust
1/75 Ellice Road, Glenfield, Auckland, 0629 New Zealand
9(2)(a) - Privacy
www.SleepDrops.co.nz
Re
ased
under the Official Information Act 1982
Notice of Confidential Information:
This message is for the named person's use only. It may contain confidential, proprietary or legally privileged information. No confidentiality or privilege
is waived or lost by any mistransmission. If you receive this message in error, please immediately delete it and all copies of it from your system, destroy
any hard copies of it and notify the sender. You must not, directly or indirectly, use, disclose, distribute, print, or copy any part of this message if you are
not the intended recipient.
Thank You.
P Please consider your environmental responsibilities before printing this e-mail
From: Tony Vujnovich [
mailto:[email address]]
Sent: Tuesday, 22 September 2020 1:47 PM
To: Mark Olley <[email address]>
Subject: RE: SleepDrops International Callaghan Funding Grant
Hi Mark,
Thanks for the information, it’s certainly worth taking the conversation further. Attached is a summary of the Callaghan
Innovation grants, criteria and programs as well as a guide to help identify the projects core R&D.
I look forward to meeting you and Kirsten on Thursday.
Regards
Tony Vujnovich
From: Mark Olley <
[email address]>
Sent: Tuesday, 22 September 2020 11:45 AM
To: Tony Vujnovich <
[email address]>
Cc: Kirsten Taylor <
[email address]>
Subject: SleepDrops International Callaghan Funding Grant
Released
Hi Tony-
Great timing with your call this morning thank you- I have sent a meeting invite for this Thursday at our offices 2 pm.
By way of introduction please review the links to our website and the following high level detail of funding
requirements.
un
https://sleepdrops.co.nz/
https://sleepdrops.co.nz/our-team/
r the Official Information Act 1982
SleepDrops is a manufacturer of natural sleep supplements. We are an award winning company (NZ number one
sleep category with pharmacies and supermarkets) specialising in the sleep category in the retail, wholesale and
practitioner markets of NZ, Australia and the US. We have an aggressive growth strategy to expand export markets.
We will discuss this strategy at our initial meeting.
SleepDrops international is looking for funding assistance from Callaghan for the following initiatives:
1. New product development
2. Clinical trials as a means to develop and expand into new markets with an initial focus on USA and Australia.
We have already completed and been approved from a Regulatory perspective for Export expansion into these
markets (TGA,FDA)
1-
SleepDrops International is looking to develop a new formulation that meets the needs of a large niche within the
natural health sector. We need the formula to be highly effective and safe as well as licensable/patentable. We need
to have clinical trials to prove efficacy.
The product is to be a natural health supplement utilising natural ingredients which are scientifically researched for
pain relief but combined in a unique way. We want to develop this product specifically for people who have physical
pain issues such as those following an injury, a fall, a car accident. These people will be visiting a practitioner for
treatment and will be needing support for this pain and recovery.
As a natural health company that specialises in sleep we realise that pain is one of the main barriers to people
experiencing insomnia and we see this as an area that is not being addressed within the retail and practitioner sector.
With 27,000 allied practitioners in NZ alone we see this as an important area to develop and scientifically trial this
product which can then be marketed to other practitioners around the world. Estimated cost of product development
circa $90k (TBC)
2-
We are looking to commission the AUT research department or Callaghan Innovation and commission 3 clinical
trials at a cost or circa . Trials will establish the following results:
Pain relief product with specific manufacturing processes that makes the product highly effective, unique and
patentable.
Scientific evidence to meet regulatory requirements for specific markets such as Korea, Japan and China.
Estimated cost TBC but estimated in the 100k region.
Regards
Mark
Released
Mark Olley
General Manager
SleepDrops International
un1/75 Ellice Road, Wairau Valley, Auckland, New Zealand
r the Official Information Act 1982
9(2)(a) - Privacy
www.SleepDrops.co.nz
Notice of Confidential Information:
This message is for the named person's use only. It may contain confidential, proprietary or legally privileged information. No confidentiality or privilege
is waived or lost by any mistransmission. If you receive this message in error, please immediately delete it and all copies of it from your system, destroy
any hard copies of it and notify the sender. You must not, directly or indirectly, use, disclose, distribute, print, or copy any part of this message if you are
not the intended recipient.
Thank You.
P Please consider your environmental responsibilities before printing this e-mail
CAUTION: This email message and any attachments contain information that may be confidential and
may be LEGALLY PRIVILEGED. If you are not the intended recipient, any use, disclosure or copying
of this message or attachments is strictly prohibited. If you have received this email message in error
Released
please notify us immediately and erase all copies of the message and attachments. We do not accept
responsibility for any viruses or similar carried with our email, or any effects our email may have on the
recipient computer system or network. Any views expressed in this email may be those of the individual
sender and may not necessarily reflect the views of Auckland Tourism, Events and Economic
Development Ltd.
Tony Vujnovich <[email address]>
26 February 2021 at 09:43
To: Kirsten Taylor <[email address]>
un
Cc: "[email address]" <[email address]>
Hi Kirsten,
r the Official Information Act 1982
I understood from Mark Olley that he was working with Mark Robinson of the Health Sector Team at Callaghan. Mark
Robinson should be able to update you on what progress was made.
Regards
Tony Vujnovich
From: Kirsten Taylor <
[email address]>
Sent: Thursday, 25 February 2021 3:21 PM
To: Tony Vujnovich <
[email address]>
Subject: RE: SleepDrops International Callaghan Funding Grant follow up
HI Tony, Did you introduce someone to Mark?
It is my understanding that we never got an introduction from you to connect with anyone.
If you did introduce someone to Mark, please send me that information and I will follow up with that person.
Thank you and have a lovely holiday.
Kirsten
From: Tony Vujnovich [
mailto:[email address]]
Sent: Thursday, 25 February 2021 1:22 PM
To: Kirsten Taylor <
[email address]>
Subject: RE: SleepDrops International Callaghan Funding Grant follow up
Hi Kirsten,
Sorry for the slow response, I was trying to get a response from the Callaghan account manager who was working
with Mark without any luck.
I’m on leave next week but could meet with you on Tuesday 9 February at 9.30 if that suits.
[Quoted text hidden]
Mark Robinson <[email address]>
26 February 2021 at 10:06
To: Kirsten Taylor <[email address]>
Cc: Tony Vujnovich <[email address]>
ReHi Kirsten,
Apologies for the circuitous route it has taken to reach me. I had drafted a note to Tony updating him of contact with
Mark but was on extended annual leave and out of the office and somehow missed sending it.
I am more than happy to touch base with you and pick up where things were left with Mark. I originally spoke with
ased
Mark September last year and then followed up in October where we covered off the following:
1-
New product development
2-
Clinical trials as a means to develop and expand into new markets with an initial focus on USA and Australia.
We have already completed and been approved from a Regulatory perspective for Export expansion into these
under the Official Information Act 1982
markets (TGA,FDA)
Since that point I have had no further contact with Sleep Drops and had assumed the company was re-evaluating its
R&D Strategy and hence would engage with Callaghan Innovation at the appropriate time which clearly is now.
I will give you a call this afternoon otherwise feel free to call me after mid-day today or by email at any time.
Ngā mihi,
Mark Robinson
Business Innovation Advisor
Health & Digital
Textile Centre, 1 Watt Street, Parnell, Auckland 1052
PO Box 2225 Shortland Street, Auckland
Mob: 9(2)(a) - Privacy
www.callaghaninnovation.govt.nz
[Quoted text hidden]
image003.jpg
5K
Kirsten Taylor <[email address]>
26 February 2021 at 14:11
To: Mark Robinson <[email address]>
Cc: Tony Vujnovich <[email address]>
Hi Mark. I was told by Mark Olley there was no opportunity for support from Callaghan.
I found out this was not true.
Most disappointing.
I'd been keen to progress my product developments and clinical trials.
ReThank you
Kirsten
9(2)(a) ased
- Privacy
Sent from my Galaxy
[Quoted text hidden]
[Quoted text hidden]
under the Official Information Act 1982
This electronic transmission and any documents accompanying this electronic transmission contain confidential information belonging to the sender. This
information may be legally privileged. The information is intended only for the use of the individual or entity named above. If you are not the intended
recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on or regarding the contents of this
electronically transmitted information is strictly prohibited.
To ensure compliance with legal requirements and to maintain cyber security standards, our IT systems are subject to ongoing monitoring, activity
logging and auditing. This monitoring and auditing service may be provided by third parties. Such third parties can access information transmitted to,
processed by and stored on our IT systems.
Kirsten Taylor <[email address]>
25 March 2021 at 15:56
To: Mark Robinson <[email address]>
Cc: Tony Vujnovich <[email address]>
HI Mark, How are you?
I have le 2 messages on your phone since receiving your email below.
I really do urgently need assistance now.
It’s been many months and AUT are on hold wai ng to kick the trial off for us.
I am worried we are going to lose some elite athletes as they will head off to the Olympics.
9(2)(a) - Privacy
Please can I have some assistance.
I have a very exci ng and innova ve product range I wish to develop and help the world with.
I checked with Callaghan. My correct mobile number is on file but just in case you don’t have it, it is:
9(2)(a) - Privacy
Thank you so much in advance.
Kirsten
From: Mark Robinson [mailt
o:[email address]]
Sent: Friday, 26 February 2021 10:07 AM
To: Kirsten Taylor <
[email address]>
Cc: Tony Vujno
vich <[email address]>
Subject: Re: SleepDrops Interna onal Callaghan Funding Grant follow up
Re
Hi Kirsten,
ased
Apologies for the circuitous route it has taken to reach me. I had drafted a note to Tony updating him of contact with
Mark but was on extended annual leave and out of the office and somehow missed sending it.
I am more than happy to touch base with you and pick up where things were left with Mark. I originally spoke with
Mark September last year and then followed up in October where we covered off the following:
under the Official Information Act 1982
1-
New product development
2-
Clinical trials as a means to develop and expand into new markets with an initial focus on USA and Australia.
We have already completed and been approved from a Regulatory perspective for Export expansion into these
markets (TGA,FDA)
Since that point I have had no further contact with Sleep Drops and had assumed the company was re-evaluating its
R&D Strategy and hence would engage with Callaghan Innovation at the appropriate time which clearly is now.
I will give you a call this afternoon otherwise feel free to call me after mid-day today or by email at any time.
Ngā mihi,
Mark Robinson
Business Innovation Advisor
Health & Digital
T
extile Centre, 1 Watt Street, Parnell, Auckland 1052
PO Box 2225 Shortland Street, Auckland
[mobile number](2)(a) - Privacy
www.callaghaninnovation.govt.nz
[Quoted text hidden]
This electronic transmission and any documents accompanying this electronic transmission contain confidential
information belonging to the sender. This information may be legally privileged. The information is intended only for
the use of the individual or entity named above. If you are not the intended recipient, you are hereby notified that
any disclosure, copying, distribution or the taking of any action in reliance on or regarding the contents of this
Reelectronically transmitted information is strictly prohibited.
[Quoted text hidden]
ased
Mark Robinson <[email address]>
26 March 2021 at 15:55
To: Kirsten Taylor <[email address]>
https://gazette.govt.nz/notice
under the Official Information Act 1982
Ngā mihi,
Mark Robinson
Business Innovation Advisor
Health & Digital
Textile Centre, 1 Watt Street, Parnell, Auckland 1052
PO Box 2225 Shortland Street, Auckland
Mob: 9(2)(a) - Privacy
www.callaghaninnovation.govt.nz
[Quoted text hidden]
image003.jpg
5K
Mark Robinson <[email address]>
26 March 2021 at 16:06
To: Kirsten Taylor <[email address]>
https://gazette.govt.nz/notice/id/2018-go4864
Ngā mihi,
Mark Robinson
Business Innovation Advisor
ReHealth & Digital
ased
Textile Centre, 1 Watt Street, Parnell, Auckland 1052
PO Box 2225 Shortland Street, Auckland
under the Official Information Act 1982
Mob: 9(2)(a) - Privacy
www.callaghaninnovation.govt.nz
[Quoted text hidden]
image003.jpg
5K
